DURECT (DRRX) Reaches $2.03 After 7.00% Down Move; Longwood Capital Partners Upped Its Rockwell Med (Put) (RMTI) Stake

April 23, 2018 - By Clifton Ray

DURECT Corporation (NASDAQ:DRRX) Logo

The stock of DURECT Corporation (NASDAQ:DRRX) is a huge mover today! The stock decreased 4.03% or $0.085 during the last trading session, reaching $2.025. About 558,570 shares traded. DURECT Corporation (NASDAQ:DRRX) has risen 121.75% since April 23, 2017 and is uptrending. It has outperformed by 110.20% the S&P500.The move comes after 8 months negative chart setup for the $310.51 million company. It was reported on Apr, 23 by Barchart.com. We have $1.88 PT which if reached, will make NASDAQ:DRRX worth $21.74 million less.

Longwood Capital Partners Llc increased Rockwell Med Inc (Put) (RMTI) stake by 76% reported in 2017Q4 SEC filing. Longwood Capital Partners Llc acquired 190,000 shares as Rockwell Med Inc (Put) (RMTI)’s stock declined 13.46%. The Longwood Capital Partners Llc holds 440,000 shares with $2.56 million value, up from 250,000 last quarter. Rockwell Med Inc (Put) now has $284.47M valuation. The stock decreased 1.88% or $0.105 during the last trading session, reaching $5.495. About 50,571 shares traded. Rockwell Medical, Inc. (NASDAQ:RMTI) has declined 16.75% since April 23, 2017 and is downtrending. It has underperformed by 28.30% the S&P500.

Investors sentiment decreased to 0.86 in Q4 2017. Its down 0.06, from 0.92 in 2017Q3. It turned negative, as 6 investors sold RMTI shares while 23 reduced holdings. 6 funds opened positions while 19 raised stakes. 10.75 million shares or 1.01% more from 10.64 million shares in 2017Q3 were reported. Ameritas Investment Inc reported 3,471 shares stake. Northern Tru invested 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI). Morgan Stanley reported 211,700 shares. Blackrock Inc accumulated 0% or 3.05 million shares. Tiaa Cref Investment Mgmt Limited Company holds 119,662 shares or 0% of its portfolio. Royal Financial Bank Of Canada reported 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI). Stifel stated it has 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI). One Trading Limited Partnership has 0% invested in Rockwell Medical, Inc. (NASDAQ:RMTI) for 27,160 shares. Sei Invests Com has invested 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI). Moreover, State Common Retirement Fund has 0% invested in Rockwell Medical, Inc. (NASDAQ:RMTI) for 40,600 shares. Manufacturers Life Insur The owns 0% invested in Rockwell Medical, Inc. (NASDAQ:RMTI) for 38,725 shares. Millennium Mgmt Limited Company has invested 0% in Rockwell Medical, Inc. (NASDAQ:RMTI). Cranbrook Wealth Mngmt Ltd Llc stated it has 2,262 shares or 0.01% of all its holdings. Metropolitan Life Insurance holds 0% or 13,251 shares. Bancorp Of Mellon Corp owns 232,925 shares for 0% of their portfolio.

Among 2 analysts covering Rockwell Medical (NASDAQ:RMTI), 0 have Buy rating, 2 Sell and 0 Hold. Therefore 0 are positive. Rockwell Medical had 6 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Saturday, August 22 with “Outperform”. The firm has “Sell” rating by TheStreet given on Thursday, August 13. Oppenheimer maintained it with “Outperform” rating and $26 target in Thursday, August 6 report. Morgan Stanley initiated the shares of RMTI in report on Thursday, August 13 with “Underweight” rating. Bank of America downgraded the stock to “Underperform” rating in Tuesday, November 8 report.

Longwood Capital Partners Llc decreased Invitae Corp stake by 375,700 shares to 152,300 valued at $1.38 million in 2017Q4. It also reduced Iovance Biotherapeutics Inc (Call) stake by 3.42 million shares and now owns 11,000 shares. Edge Therapeutics Inc was reduced too.

Since December 15, 2017, it had 0 buys, and 1 sale for $235 activity. Shares for $235 were sold by Richmond David S..

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company has market cap of $310.51 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. It currently has negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.

Investors sentiment decreased to 2.04 in 2017 Q4. Its down 0.01, from 2.05 in 2017Q3. It turned negative, as 9 investors sold DURECT Corporation shares while 16 reduced holdings. 17 funds opened positions while 34 raised stakes. 64.77 million shares or 0.77% less from 65.27 million shares in 2017Q3 were reported. Tiaa Cref Invest Management Lc holds 481,229 shares or 0% of its portfolio. 127,315 were reported by Manufacturers Life Ins Company The. Jane Street Group Inc Ltd Liability Corp owns 14,572 shares for 0% of their portfolio. Tocqueville Asset Management Lp owns 1.22 million shares. California State Teachers Retirement owns 226,149 shares. 24,000 were accumulated by Cornerstone Cap. 19,652 are owned by First Quadrant Ltd Partnership Ca. Jpmorgan Chase & stated it has 30,951 shares or 0% of all its holdings. Qs Investors Limited Company has invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Jacobs Levy Equity Management reported 186,466 shares stake. Amer Grp Inc invested in 96,639 shares or 0% of the stock. State Street has 2.31 million shares for 0% of their portfolio. New York State Common Retirement Fund invested in 102,300 shares or 0% of the stock. Deutsche Commercial Bank Ag invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). New York-based Art Advisors Ltd Co has invested 0.01% in DURECT Corporation (NASDAQ:DRRX).

Analysts await DURECT Corporation (NASDAQ:DRRX) to report earnings on May, 9. They expect $-0.06 EPS, 0.00% or $0.00 from last year’s $-0.06 per share. After $0.05 actual EPS reported by DURECT Corporation for the previous quarter, Wall Street now forecasts -220.00% negative EPS growth.

Among 3 analysts covering Durect (NASDAQ:DRRX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Durect had 8 analyst reports since April 25, 2016 according to SRatingsIntel. The stock of DURECT Corporation (NASDAQ:DRRX) has “Hold” rating given on Friday, October 20 by Stifel Nicolaus. H.C. Wainwright downgraded the shares of DRRX in report on Friday, October 20 to “Neutral” rating. The stock of DURECT Corporation (NASDAQ:DRRX) earned “Buy” rating by H.C. Wainwright on Monday, August 14. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 6. H.C. Wainwright maintained DURECT Corporation (NASDAQ:DRRX) rating on Friday, June 23. H.C. Wainwright has “Buy” rating and $300 target. The rating was upgraded by Stifel Nicolaus to “Buy” on Wednesday, July 12. Rodman & Renshaw initiated it with “Buy” rating and $4 target in Monday, April 25 report. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, March 2.

DURECT Corporation (NASDAQ:DRRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: